List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5838637/publications.pdf Version: 2024-02-01



ADAM | FLEMING

#	Article	IF	CITATIONS
1	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
2	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	7.7	799
3	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 2012, 124, 615-625.	7.7	376
4	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	7.7	250
5	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
6	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
7	Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. European Journal of Cancer, 2012, 48, 353-359.	2.8	186
8	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	21.4	167
9	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
10	Brain Tumors in Children. Current Problems in Pediatric and Adolescent Health Care, 2012, 42, 80-103.	1.7	53
11	Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. Journal of Pathology, 2020, 251, 249-261.	4.5	53
12	Survival Following Tumor Recurrence in Children With Medulloblastoma. Journal of Pediatric Hematology/Oncology, 2018, 40, e159-e163.	0.6	46
13	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	2.9	43
14	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor Neuropsychology, 2016, 30, 425-438.	1.3	42
15	Wnt activation as a therapeutic strategy in medulloblastoma. Nature Communications, 2020, 11, 4323.	12.8	34
16	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986–2006. Brain Pathology, 2012, 22, 625-635.	4.1	29
17	Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience. Pediatric Blood and Cancer, 2015, 62, 1265-1269.	1.5	29
18	Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and metaâ€analysis. Clinical Obesity, 2018, 8, 55-67.	2.0	29

#	Article	IF	CITATIONS
19	Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26538.	1.5	22
20	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncology, 2021, 7, 1806.	7.1	22
21	Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 2015, 124, 247-253.	2.9	20
22	Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 2017, 133, 539-552.	2.9	16
23	Incidence of medulloblastoma in Canadian children. Journal of Neuro-Oncology, 2014, 120, 575-579.	2.9	14
24	A novel approach to total skin irradiation using helical TomoTherapy. Practical Radiation Oncology, 2014, 4, 330-335.	2.1	14
25	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	2.8	13
26	Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. Human Pathology, 2017, 59, 125-130.	2.0	11
27	Tri-ponderal mass index in survivors of childhood brain tumors: A cross-sectional study. Scientific Reports, 2018, 8, 16336.	3.3	11
28	The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. Obesity Reviews, 2017, 18, 899-914.	6.5	10
29	Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study). Scientific Reports, 2017, 7, 45078.	3.3	9
30	Circulating leptin levels are associated with adiposity in survivors of childhood brain tumors. Scientific Reports, 2020, 10, 4711.	3.3	9
31	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	2.9	8
32	Predictive measures and outcomes of extent of resection in juvenile pilocytic astrocytoma. Journal of Clinical Neuroscience, 2019, 70, 79-84.	1.5	6
33	Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors. Journal of Clinical Oncology, 2021, 39, JCO.21.00018.	1.6	6
34	Evaluating overweight and obesity prevalence in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews, 2017, 6, 43.	5.3	5
35	Bariatric interventions in obesity treatment and prevention in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer and Metastasis Reviews, 2020, 39, 79-90.	5.9	5
36	Combined Neutrophil and Erythrocyte Agglutination in a 7-year-old Boy. Journal of Pediatric Hematology/Oncology, 2007, 29, 664-665.	0.6	4

#	Article	IF	CITATIONS
37	Exploring the Attitudes of Pediatric Oncologists Toward the Use of Laxatives for the Prevention of Constipation in Patients Undergoing Active Treatment: A Canadian Perspective. Pediatric Hematology and Oncology, 2014, 31, 448-457.	0.8	4
38	The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews, 2016, 5, 101.	5.3	4
39	Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. Canadian Journal of Neurological Sciences, 2019, 46, 403-414.	0.5	4
40	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. Pediatric Blood and Cancer, 2019, 66, e27540.	1.5	4
41	Analysis of factors that influence neurosurgical length of hospital stay among newly diagnosed pediatric brain tumor patients. Pediatric Blood and Cancer, 2020, 67, e28041.	1.5	4
42	Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol. Systematic Reviews, 2020, 9, 47.	5.3	4
43	Myalgia and Hematuria in Association with Clonidine and Arginine Administration for Growth Hormone Stimulation Tests. Case Reports in Medicine, 2020, 2020, 1-4.	0.7	3
44	Late effects care for childhood brain Tumor Survivors: A Quality-Improvement Initiative. Pediatric Hematology and Oncology, 2022, 39, 291-303.	0.8	3
45	Birth weight and body mass index z-score in childhood brain tumors: A cross-sectional study. Scientific Reports, 2018, 8, 1642.	3.3	2
46	High molecular weight adiponectin levels are inversely associated with adiposity in pediatric brain tumor survivors. Scientific Reports, 2020, 10, 18606.	3.3	2
47	42 - The Prevalence of Diabetes Mellitus in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis. Canadian Journal of Diabetes, 2020, 44, S19.	0.8	2
48	Frosted Branch Angiitis Associated With Cytomegalovirus in a Pediatric Autologous Stem Cell Transplant Patient: Case Report and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2022, 44, e479-e481.	0.6	2
49	The Role of a Longitudinal, Multidisciplinary Clinic in Building a Unique Research Collaborative. Frontiers in Oncology, 2022, 12, 857699.	2.8	2
50	PS1 - 176 Where Have All the Fat Cells Gone? A Comparative Analysis of Adiposity Patterns in Childhood Brain Tumor Survivors and Non-Cancer Controls. Canadian Journal of Neurological Sciences, 2016, 43, S11-S11.	0.5	1
51	Evaluating the prevalence of diabetes mellitus subtypes in childhood cancer survivors: a systematic review protocol. Adolescent Health, Medicine and Therapeutics, 2019, Volume 10, 59-65.	0.9	1
52	Childhood head trauma and the risk of childhood brain tumours: A case ontrol study in Ontario, Canada. International Journal of Cancer, 2022, 150, 795-801.	5.1	1
53	Epidemiology of malignant pontine gliomas (MPG) in the paediatric population in Canada: A study of the Canadian paediatric brain tumour consortium (CPBTC). Canadian Journal of Neurological Sciences, 2014, 41, S16-S16.	0.5	0
54	CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. Neuro-Oncology, 2016, 18, iii16.2-iii16.	1.2	0

#	Article	IF	CITATIONS
55	EPI-04DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. Neuro-Oncology, 2016, 18, iii40.3-iii40.	1.2	0
56	AT-03ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT?. Neuro-Oncology, 2016, 18, iii1.2-iii1.	1.2	0
57	A.03 Analyses of surgical and MRI factors associated with cerebellar mutism. Canadian Journal of Neurological Sciences, 2017, 44, S9-S9.	0.5	0
58	Adiposity and depressive symptoms in survivors of childhood brain tumors: A report from the Canadian study of the determinants of endometabolic health in children. Journal of the Neurological Sciences, 2017, 381, 746.	0.6	0
59	EPID-17. AÂSINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology, 2017, 19, vi72-vi72.	1.2	0
60	MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i133-i133.	1.2	0
61	P.044 Salvage therapy in recurrent pediatric medulloblastoma: A single centre experience. Canadian Journal of Neurological Sciences, 2018, 45, S27-S27.	0.5	0
62	MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology, 2018, 20, i119-i119.	1.2	0
63	MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii112-ii113.	1.2	0
64	Leptin is Associated with the Tri-Ponderal Mass Index in Children: A Cross-Sectional Study. Adolescent Health, Medicine and Therapeutics, 2021, Volume 12, 9-15.	0.9	0
65	EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. Neuro-Oncology, 2021, 23, i49-i49.	1.2	0
66	Abstract 148: Canonical Wnt activation as a therapeutic strategy in pediatric medulloblastoma. , 2018, ,		0
67	QOL-02. PERCEPTIONS OF LATE EFFECTS CARE NEEDS AMONG SURVIVORS OF PEDIATRIC BRAIN TUMOURS. Neuro-Oncology, 2020, 22, iii431-iii431.	1.2	0
68	MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii399-iii399.	1.2	0
69	QOL-46. LATE EFFECTS CARE FOR CHILDHOOD BRAIN TUMOUR SURVIVORS: A QUALITY IMPROVEMENT PROJECT. Neuro-Oncology, 2020, 22, iii439-iii439.	1.2	0
70	A single center experience in the management of progressive juvenile pilocytic astrocytoma. Journal of Neurosurgical Sciences, 2021, , .	0.6	0
71	C.5 Musashi-1 is a master regulator of aberrant translation in MYC-amplified Group 3 medulloblastoma. Canadian Journal of Neurological Sciences, 2021, 48, S19-S19.	0.5	0